Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

4D Molecular Therapeutics, Inc.

NASDAQ: FDMT · Life Sciences · 6 alerts · CIK 1650648

Share price
$11.29Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All 4D Molecular Therapeutics, Inc. filings on SEC EDGAR ↗

8:06 AM ET 8-K
Clinical Trial Data

4D Molecular Therapeutics Clinical Trial Data

4D Molecular Therapeutics announced the enrollment of the first patients in its 4SIGHT Phase 3 clinical trial evaluating 4D-150 for diabetic macular edema (DME). The company also released positive 2-year data from its SPECTRA clinical trial, showing 4D-150 was well tolerated with a 61% reduction in treatment burden compared to standard aflibercept injections.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.